This panel provides drug-protein interaction and their ADRs along with references
| Toxicity |
Interacting Protein |
Mechanism |
Reference |
| Bradycardia | Cytochrome P450 3A4 (P08684) | Concomitant using of adrenaline and propranolol produces marked inhibition of CYP3A4@ which leads to significant high blood pressure@slow heart beat@atrioventricular block [ ADR Type 4 ] | Failure of propranolol to prevent tilt-evoked systemic vasodilatation, adrenaline release, and neurocardiogenic syncope
|
| Carcinogenicity | CYP1A (P04798) | Propranolol may lead to complications in drug therapy and modulate the toxicity or carcinogenicity of drugs that are substrates for the CYP1A1(reserpine) [ ADR Type 4 ] | Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats
|
| Impairs Oxidative Phosphorylation | Mg2+ transport ATPase (Q63080) | Propranolol impairs oxidative phosphorylation mainly through its inhibition of the Mg2+-ATPase activity of the mitochondria [ ADR Type 2 ] | Inhibition of the mitochondrial Mg2+-ATPase by propranolol
|
| Impairs The Mitochondrial Respiration | Mg2+ transport ATPase (Q63080) | Propranolol impairs the mitochondrial respiration mainly through its inhibition of the Mg2+-ATPase activity of the mitochondria. [ ADR Type 2 ] | Inhibition of the mitochondrial Mg2+-ATPase by propranolol
|
| Increased Beta-Blockade | CYP2D6 (P10635) | Increased beta-blockade [ ADR Type 1 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW
|
| Low Blood Pressure | Cytochrome P450 3A4 (P08684) | Concomitant using of monoamine oxidase inhibitor and propranolol produces marked inhibition of CYP3A4@ which leads to very low blood pressure. [ ADR Type 4 ] | Eletriptan issues Headache
|
| Proarrhythmia | CYP2D6 (P10635) | Proarrhythmic and other toxic effects [ ADR Type 2 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW
|
| Sudden Cardiac Death | Potassium voltage-gated channel subfamily E member 1 (P15382) | Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] | Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
|
| Sudden Cardiac Death | Potassium voltage-gated channel subfamily H member 2 (Q12809) | Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] | Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
|
| Sudden Cardiac Death | Potassium voltage-gated channel subfamily KQT member 1 (P51787) | Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] | Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
|
| Sudden Cardiac Death | Sodium channel protein type 5 subunit alpha (Q14524) | Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] | Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
|